thiazolidines has been researched along with Diabetic Neuropathies in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (13.21) | 18.7374 |
| 1990's | 14 (26.42) | 18.2507 |
| 2000's | 17 (32.08) | 29.6817 |
| 2010's | 10 (18.87) | 24.3611 |
| 2020's | 5 (9.43) | 2.80 |
| Authors | Studies |
|---|---|
| Sato, K | 1 |
| DiPrimio, N; Iyer, S; Lao, J; Morava, E; Murthy, K; Parton, Z; Perlstein, EO; Preston, G; Sam, FS; Tsang, H; Verheijen, J | 1 |
| Guo, D; Kudo, K; Mizukami, H; Ogasawara, S; Osonoi, S; Sasaki, T; Takahashi, K; Yagihashi, S | 1 |
| Chahal, S; Syngle, A; Vohra, K | 1 |
| Choudhary, S; Kumar, M; Silakari, O | 1 |
| Choudhary, S; Silakari, O | 1 |
| Lin, HX; Lu, YK; Wang, XT; Xu, SA | 1 |
| Jin, Y; Lin, H; Wang, X; Xu, S; Zhang, R | 1 |
| Jaiswal, S; Mishra, S; Shengule, S; Torgal, SS | 1 |
| Gupta, A; Gupta, Y | 1 |
| Abe, N; Murao, Y; Sato, K; Tampo, Y; Tatsunami, R; Yama, K | 1 |
| Amizuka, N; Fujie, A; Hao, W; Hasegawa, T; Katsuyama, E; Kobayashi, T; Matsumoto, M; Miyamoto, K; Miyamoto, T; Morioka, H; Morita, M; Nakamura, M; Sato, Y; Tando, T; Tashiro, S; Toyama, Y; Watanabe, R | 1 |
| Feng, Z; Kusunoki, M; Nakamura, T; Nishina, A; Sato, D; Shinzawa, G | 1 |
| Atsumi, Y; Baba, M; Hotta, N; Kawamori, R; Kishikawa, H; Nakamura, J; Oikawa, S; Shigeta, Y; Yamada, N; Yasuda, H | 1 |
| Baba, M | 2 |
| Atarashi, H; Ibuki, C; Ishii-Nozawa, R; Ito, A; Kataoka, H; Takeuchi, K | 1 |
| Fukuda, M; Hotta, N; Kawamori, R; Shigeta, Y | 1 |
| Uesaka, Y | 1 |
| Chikamori, K; Ito, S; Kimura, M; Nakaya, Y; Nomura, M; Okamoto, H; Saito, K; Uehara, K | 1 |
| Chung, RP; Darmanin, C; El-Kabbani, O; Ruiz, F | 1 |
| Ueda, H | 1 |
| Nakamura, J | 1 |
| Hattori, T; Kanai, K; Kuwabara, S; Misawa, S; Nakata, M; Sawai, S; Tamura, N; Yagui, K | 1 |
| Baba, M; Kimura, K; Suda, T; Yagihashi, S | 1 |
| Akanuma, Y; Hotta, N; Kawamori, R; Matsuoka, K; Nakashima, M; Oka, Y; Sakamoto, N; Shichiri, M; Shigeta, Y; Toyota, T; Yoshimura, I | 1 |
| Akanuma, Y; Hotta, N; Kawamori, R; Matsuoka, K; Oka, Y; Sakamoto, N; Shichiri, M; Shigeta, Y; Toyota, T | 1 |
| Borja, NL; Ramirez, MA | 1 |
| Hatanaka, I; Kikkawa, R; Kobayashi, N; Morimura, T; Shigeta, Y; Terashima, H; Tsuboshima, M; Yasuda, H | 1 |
| Hatanaka, I; Kikkawa, R; Kobayashi, N; Shigeta, Y; Yasuda, H | 1 |
| Goto, Y; Hotta, N; Kikkawa, R; Sakamoto, N; Shigeta, Y | 1 |
| Goto, Y; Hotta, N; Kikkawa, R; Kito, S; Matsuoka, K; Sakamoto, N; Sakuma, A; Shigeta, Y; Takahashi, A | 1 |
| Nakamura, T; Okano, R; Okuda, S; Seo, Y; Uchiyama, H | 1 |
| Kurata, C; Mikami, T; Okayama, K; Shouda, S; Sugiyama, T; Tawarahara, K; Wakabayashi, Y | 1 |
| Hotta, N | 1 |
| Aono, T; Fujita, T; Hamada, M; Hayakawa, N; Hayashi, R; Itoh, M; Kakizawa, H; Makino, M; Nagasaka, A; Nagata, M; Shinohara, R; Uchimura, K | 1 |
| Furukawa, S; Hayashi, K; Matsukura, S; Ohi, T; Ohta, M; Saita, K | 1 |
| Inaba, M; Kawagishi, T; Kyogoku, I; Miki, T; Morii, H; Nishizawa, Y; Okuno, Y; Shimada, H | 1 |
| Kariyone, S; Nakatani, Y; Narabayashi, I; Onishi, S; Saika, Y; Tamura, K; Utsunomiya, K | 1 |
| Nakatani, Y; Narabayashi, I; Onishi, S; Tamura, K; Utsunomiya, K | 1 |
| Ikeda, T; Iwata, K; Tanaka, Y | 1 |
| Haneda, M; Hirai, A; Joko, M; Kashiwagi, A; Kawabata, T; Kikkawa, R; Maeda, K; Maeda, T; Terada, M; Yasuda, H | 1 |
| Hamada, Y; Horiuchi, S; Hotta, N; Kasuya, Y; Kato, K; Komori, T; Nagai, R; Nakamura, J; Naruse, K | 1 |
| Chaya, S; Hamada, Y; Hotta, N; Kamiya, H; Koh, N; Mizubayashi, R; Nakamura, J; Nakayama, M; Yasuda, Y | 1 |
| Ishikawa, Y; Nakano, M; Nishizawa, Y; Takeuchi, M; Wada, R; Yagihashi, N; Yagihashi, S; Yasumura, K | 1 |
| Aida, K; Onaya, T; Shindo, H; Tawata, M | 1 |
| Kato, K; Miwa, I; Mizota, M; Nakayama, K; Okuda, J | 1 |
| Iwamoto, Y | 1 |
| Hatanaka, I; Huitian, Z; Shigeta, Y; Sonobe, M; Terada, M; Yamashita, M; Yasuda, H | 1 |
| Kondo, M; Nakano, K; Nishioka, H; Terashima, H; Yoshida, T; Yoshioka, K | 1 |
| Akiguchi, I; Kuriya, N; Miyake, S; Mori, T; Nakanishi, T; Takahashi, A; Toyama, K; Ueda, Y; Yamaguchi, Y; Yokota, A | 1 |
| Fukasawa, H; Hotta, N; Iida, M; Kakuta, H; Kimura, M; Koh, N; Morimura, T; Sakamoto, N; Terashima, H | 1 |
| Kador, PF; Kinoshita, JH; Sharpless, NE | 1 |
9 review(s) available for thiazolidines and Diabetic Neuropathies
| Article | Year |
|---|---|
[Elucidation and Application of Novel Action of Therapeutic Agents for Diabetic Neuropathy].
Topics: Aldehyde Reductase; Antioxidants; Cadmium; Chelating Agents; Diabetes Mellitus; Diabetic Neuropathies; Endothelial Cells; Environmental Pollutants; Glutathione; Humans; Ligases; Metallothionein; NF-E2-Related Factor 2; Reactive Oxygen Species; Rhodanine; Thiazolidines | 2022 |
Lipoic Acid Combined with Epalrestat versus Lipoic Acid in Treating Diabetic Peripheral Neuropathy:A Meta-analysis.
Topics: Diabetic Neuropathies; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Rhodanine; Thiazolidines; Thioctic Acid | 2017 |
[Progress in therapy for and diagnosis of diabetic neuropathies].
Topics: Achilles Tendon; Aldehyde Reductase; Animals; Antidepressive Agents, Tricyclic; Atrophy; Diabetic Neuropathies; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Leg; Muscle, Skeletal; Pain Measurement; Reflex; Rhodanine; Skin; Thiazolidines; Vibration | 2009 |
[Prevention and treatment of diabetic neuropathy].
Topics: Aldehyde Reductase; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Chronic Disease; Diabetic Neuropathies; Enzyme Inhibitors; gamma-Linolenic Acid; Glycation End Products, Advanced; Guanidines; Humans; Insulin; Oxidative Stress; Rhodanine; Thiazolidines | 2002 |
[Nerve flow dynamics in the pathogenesis of diabetic neuropathy].
Topics: Aldehyde Reductase; Animals; Capillaries; Capillary Permeability; Diabetic Neuropathies; Enzyme Inhibitors; Genetic Therapy; Hepatocyte Growth Factor; Humans; Ischemia; Oxidative Stress; Peripheral Nerves; Regional Blood Flow; Reperfusion Injury; Rhodanine; Thiazolidines; Vascular Endothelial Growth Factor A | 2005 |
[Development of therapeutic agents for diabetic neuropathies].
Topics: Aldehyde Reductase; Antioxidants; C-Peptide; Diabetic Neuropathies; Drug Design; Enzyme Inhibitors; Genetic Therapy; Glycation End Products, Advanced; Hedgehog Proteins; Humans; Indoles; Maleimides; Nerve Growth Factor; Oxidative Stress; Polymers; Protein Kinase C; Rhodanine; Thiadiazoles; Thiamine; Thiazoles; Thiazolidines; Trans-Activators; Vascular Endothelial Growth Factor A | 2005 |
Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Topics: Aldehyde Reductase; Animals; Clinical Trials as Topic; Diabetic Neuropathies; Humans; Rhodanine; Thiazolidines | 2008 |
[Epalrestat].
Topics: Aldehyde Reductase; Blood Glucose; Clinical Trials as Topic; Depression, Chemical; Diabetic Neuropathies; Enzyme Inhibitors; Free Radicals; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Multicenter Studies as Topic; Protein Precursors; Rhodanine; Thiazolidines | 1997 |
Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Topics: Aldehyde Reductase; Animals; Binding Sites; Blood Glucose; Cataract; Chemical Phenomena; Chemistry; Corneal Diseases; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Models, Animal; Fluorenes; Galactose; Humans; Hydantoins; Imidazoles; Imidazolidines; Models, Molecular; Naphthalenes; Phthalazines; Rhodanine; Sorbitol; Structure-Activity Relationship; Substrate Specificity; Sugar Alcohol Dehydrogenases; Thiazolidines; Tissue Distribution | 1985 |
10 trial(s) available for thiazolidines and Diabetic Neuropathies
| Article | Year |
|---|---|
Efficacy and tolerability of DPP4 inhibitor, teneligliptin, on autonomic and peripheral neuropathy in type 2 diabetes: an open label, pilot study.
Topics: Autonomic Nervous System Diseases; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Hand Strength; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrazoles; Quality of Life; Thiazolidines | 2021 |
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Female; Glycated Hemoglobin; Humans; Long-Term Care; Male; Middle Aged; Patient Selection; Proteinuria; Rhodanine; Thiazolidines; Treatment Outcome | 2008 |
Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
Topics: Adult; Aged; Aged, 80 and over; Aldehyde Reductase; Carpal Tunnel Syndrome; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ion Transport; Male; Median Nerve; Middle Aged; Neural Conduction; Reaction Time; Rhodanine; Sodium; Sodium Channels; Thiazolidines | 2006 |
Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients.
Topics: Action Potentials; Aldehyde Reductase; Diabetes Mellitus; Diabetic Neuropathies; Double-Blind Method; Electric Stimulation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neural Conduction; Reaction Time; Rhodanine; Thiazolidines | 2006 |
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
Topics: Adult; Aged; Aldehyde Reductase; Blood Glucose; Diabetic Angiopathies; Diabetic Neuropathies; Enzyme Inhibitors; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Neural Conduction; Rhodanine; Thiazolidines | 2006 |
A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT).
Topics: Age of Onset; Aged; Aldehyde Reductase; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enzyme Inhibitors; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Motor Neurons; Neural Conduction; Prospective Studies; Rhodanine; Thiazolidines | 2007 |
Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study.
Topics: Aged; Aldehyde Reductase; Arm; Blood Glucose; Diabetic Neuropathies; Double-Blind Method; Enzyme Inhibitors; Female; Heart Rate; Humans; Male; Middle Aged; Neural Conduction; Pain; Rhodanine; Sensory Thresholds; Thiazolidines; Vibration | 1995 |
A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy.
Topics: Adult; Aldehyde Reductase; Diabetic Neuropathies; Double-Blind Method; Glycated Hemoglobin; Humans; Median Nerve; Middle Aged; Neural Conduction; Peroneal Nerve; Placebos; Rhodanine; Thiazolidines | 1993 |
Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
Topics: Aged; Aged, 80 and over; Aldehyde Reductase; Autonomic Nervous System Diseases; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Electrocardiography; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Rhodanine; Statistics, Nonparametric; Thiazolidines | 1999 |
Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diet, Diabetic; Electrocardiography; Enzyme Inhibitors; Female; Heart Rate; Humans; Hypoglycemic Agents; Insulin; Light; Male; Median Nerve; Middle Aged; Neural Conduction; Reaction Time; Reflex, Pupillary; Respiratory Mechanics; Rhodanine; Thiazolidines; Tibial Nerve | 2001 |
34 other study(ies) available for thiazolidines and Diabetic Neuropathies
| Article | Year |
|---|---|
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Topics: Aldehyde Reductase; Animals; Cells, Cultured; Congenital Disorders of Glycosylation; Diabetic Neuropathies; Disease Models, Animal; Drug Repositioning; Endoplasmic Reticulum Stress; Fibroblasts; Glycosylation; Humans; Nematoda; Phosphotransferases (Phosphomutases); Polyphenols; Rhodanine; Thiazolidines | 2019 |
Beneficial effects of combination therapy of canagliflozin and teneligliptin on diabetic polyneuropathy and β-cell volume density in spontaneously type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Canagliflozin; Cell Count; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Hypoglycemic Agents; Insulin-Secreting Cells; Islets of Langerhans; Male; Pancreas; Parasympathetic Nervous System; Pyrazoles; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines | 2020 |
QM/MM analysis, synthesis and biological evaluation of epalrestat based mutual-prodrugs for diabetic neuropathy and nephropathy.
Topics: Animals; Density Functional Theory; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dose-Response Relationship, Drug; Hypoglycemic Agents; Male; Molecular Structure; Prodrugs; Rats; Rats, Wistar; Rhodanine; Streptozocin; Structure-Activity Relationship; Thiazolidines | 2021 |
Virtual screening of epalrestat mimicking selective ALR2 inhibitors from natural product database: auto pharmacophore, ADMET prediction and molecular dynamics approach.
Topics: Biological Products; Diabetic Neuropathies; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Rhodanine; Thiazolidines | 2022 |
The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
Topics: Antioxidants; Diabetic Neuropathies; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Research Design; Rhodanine; Thiazolidines; Thioctic Acid; Treatment Outcome | 2018 |
Neuroprotective effect of epalrestat mediated through oxidative stress markers, cytokines and TAU protein levels in diabetic rats.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Cognition Disorders; Cytokines; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet, High-Fat; Hippocampus; Inflammation; Male; Neuroprotective Agents; Oxidative Stress; Rats; Rats, Wistar; Rhodanine; tau Proteins; Thiazolidines | 2018 |
Diabetic neuropathy: Part 2.
Topics: Antidepressive Agents, Tricyclic; Diabetic Foot; Diabetic Neuropathies; Enzyme Inhibitors; Humans; Hyperglycemia; Oxidative Stress; Rhodanine; Thiazolidines | 2014 |
Epalrestat increases glutathione, thioredoxin, and heme oxygenase-1 by stimulating Nrf2 pathway in endothelial cells.
Topics: Animals; Cattle; Chromones; Diabetic Neuropathies; Endothelial Cells; Gene Expression Regulation; Glutathione; Heme Oxygenase-1; Humans; Morpholines; NF-E2-Related Factor 2; Oxidative Stress; Rats; Rhodanine; Thiazolidines; Thioredoxins | 2015 |
Hyperglycemia Promotes Schwann Cell De-differentiation and De-myelination via Sorbitol Accumulation and Igf1 Protein Down-regulation.
Topics: Aldehyde Reductase; Animals; Calcitriol; Cell Dedifferentiation; Cells, Cultured; Demyelinating Diseases; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Down-Regulation; Enzyme Inhibitors; Glucose; Hyperglycemia; In Vitro Techniques; Insulin-Like Growth Factor I; Mice; Mice, Inbred C57BL; Models, Neurological; Rats; Rhodanine; Schwann Cells; Sciatic Nerve; Sorbitol; Thiazolidines; Vitamin D | 2015 |
Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
Topics: Action Potentials; Aldehyde Reductase; Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Enzyme Inhibitors; Heart Rate; Insulin; Male; Neuroprotective Agents; Rats, Wistar; Rhodanine; Sciatic Nerve; Sympathetic Nervous System; Thiazolidines | 2015 |
[Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course].
Topics: Aged; Aldehyde Reductase; Diabetic Neuropathies; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Regression Analysis; Rhodanine; Surveys and Questionnaires; Thiazolidines | 2009 |
Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neurop
Topics: Aged; Aged, 80 and over; Aldehyde Reductase; Asian People; Blood Glucose; Cost-Benefit Analysis; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Enzyme Inhibitors; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Multivariate Analysis; Neural Conduction; Rhodanine; Severity of Illness Index; Thiazolidines; Time Factors; Treatment Outcome | 2012 |
[Recent advances in treatment of diabetic polyneuropathy].
Topics: Anticonvulsants; Antidepressive Agents; Blood Glucose; Diabetic Neuropathies; Disease Progression; Humans; Pain; Rhodanine; Sensation Disorders; Thiazolidines | 2012 |
Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Topics: Aged; Aldehyde Reductase; Autonomic Nervous System; Diabetic Neuropathies; Electrodiagnosis; Enzyme Inhibitors; Female; Gastrointestinal Motility; Gastroparesis; Glycated Hemoglobin; Heart Rate; Humans; Male; Middle Aged; Rhodanine; Thiazolidines | 2003 |
Aldose reductase structures: implications for mechanism and inhibition.
Topics: Aldehyde Reductase; Animals; Databases, Factual; Diabetic Neuropathies; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Mutagenesis, Site-Directed; Protein Conformation; Rhodanine; Thiazolidines | 2004 |
Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Erythrocytes; Insulin; Male; Neural Conduction; Rats; Rats, Inbred Strains; Rhodanine; Sciatic Nerve; Sorbitol; Sugar Alcohol Dehydrogenases; Thiazoles; Thiazolidines | 1983 |
Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Male; Motor Neurons; Neural Conduction; Rats; Rats, Inbred Strains; Rhodanine; Sciatic Nerve; Sorbitol; Sugar Alcohol Dehydrogenases; Thiazoles; Thiazolidines | 1984 |
Effectiveness of aldose reductase inhibitors for diabetic gastroenteropathy with constipation.
Topics: Aldehyde Reductase; Autonomic Nervous System Diseases; Cardiovascular Diseases; Constipation; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enzyme Inhibitors; Female; Gastrointestinal Motility; Hemodynamics; Humans; Intestinal Pseudo-Obstruction; Middle Aged; Rhodanine; Shock, Septic; Thiazolidines | 1997 |
Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
Topics: 3-Iodobenzylguanidine; Aldehyde Reductase; Animals; Autonomic Nervous System Diseases; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Enzyme Inhibitors; Heart; Insulin; Iodine Radioisotopes; Male; Myocardium; Norepinephrine; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rhodanine; Thiazolidines | 1997 |
Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Blood Glucose; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Erythrocytes; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Regression Analysis; Reproducibility of Results; Rhodanine; Sorbitol; Spectrophotometry; Thiazolidines | 1998 |
Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
Topics: Aldehyde Reductase; Animals; Catechols; Cells, Cultured; Ciliary Neurotrophic Factor; Diabetic Neuropathies; Electrophysiology; Enzyme Inhibitors; Male; Nerve Growth Factors; Nerve Tissue Proteins; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Rhodanine; Schwann Cells; Sciatic Nerve; Thiazolidines | 1998 |
[Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neural Conduction; Rhodanine; Thiazolidines | 1998 |
Effects of aldose reductase inhibitor and vitamin B12 on myocardial uptake of iodine-123 metaiodobenzylguanidine in patients with non-insulin-dependent diabetes mellitus.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Aldehyde Reductase; Autonomic Nervous System Diseases; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enzyme Inhibitors; Female; Heart; Heart Diseases; Humans; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Rhodanine; Thiazolidines; Vitamin B 12 | 1998 |
I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
Topics: 3-Iodobenzylguanidine; Adult; Aldehyde Reductase; Autonomic Nervous System Diseases; Diabetic Neuropathies; Enzyme Inhibitors; Heart; Humans; Male; Radionuclide Imaging; Radiopharmaceuticals; Rhodanine; Thiazolidines | 1999 |
Effect of aldose reductase inhibitor on cutaneous nerve fiber length in diabetic patients.
Topics: Aldehyde Reductase; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enzyme Inhibitors; Humans; Nerve Fibers; Rhodanine; Skin; Thiazolidines | 2000 |
Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Topics: Aldehyde Reductase; Blood Glucose; Blood Proteins; Deoxyglucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Erythrocytes; Female; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Lysine; Male; Middle Aged; Reference Values; Rhodanine; Thiazolidines | 2000 |
Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Glycation End Products, Advanced; Male; Nerve Degeneration; Neural Conduction; Rats; Rats, Wistar; Thiadiazoles; Thiazolidines | 2001 |
The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Chalcone; Chalcones; Cyclic AMP; Cyclic GMP; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Iloprost; Inositol; Male; Neural Conduction; Rats; Rats, Inbred WKY; Rhodanine; Sciatic Nerve; Sorbitol; Thiazolidines | 1992 |
Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil.
Topics: Aldehyde Reductase; Animals; Benzofurans; Cataract; Cattle; Diabetic Neuropathies; Hydantoins; Imidazoles; Imidazolidines; In Vitro Techniques; Male; Rats; Rats, Inbred Strains; Rhodanine; Sorbitol; Thiazolidines | 1991 |
[Diabetic complication].
Topics: Aldehyde Reductase; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetic Nephropathies; Diabetic Neuropathies; Glycosylation; Humans; Inositol; Proteins; Rhodanine; Sorbitol; Thiazolidines | 1991 |
Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235.
Topics: Adenosine Triphosphate; Aldehyde Reductase; Alprostadil; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Electrophysiology; Inositol; Lactates; Male; Myelin Sheath; Nerve Fibers; Phosphocreatine; Rats; Rats, Inbred Strains; Rhodanine; Sciatic Nerve; Sorbitol; Streptozocin; Sugar Alcohol Dehydrogenases; Thiazoles; Thiazolidines | 1989 |
Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
Topics: Aldehyde Reductase; alpha-Methyltyrosine; Animals; Autonomic Nervous System Diseases; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Erythrocytes; Female; Methyltyrosines; Neural Conduction; Norepinephrine; Peripheral Nervous System Diseases; Rats; Rats, Inbred Strains; Rhodanine; Sciatic Nerve; Sorbitol; Streptozocin; Sugar Alcohol Dehydrogenases; Sympathetic Nervous System; Thiazoles; Thiazolidines; Triiodothyronine | 1987 |
Effects of aldose reductase inhibitor on the peripheral nerve function during ischemia in diabetics.
Topics: Action Potentials; Adolescent; Adult; Aldehyde Reductase; Arm; Child; Diabetic Neuropathies; Female; Humans; Ischemia; Male; Middle Aged; Peripheral Nerves; Rhodanine; Sugar Alcohol Dehydrogenases; Thiazoles; Thiazolidines | 1987 |
Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dietary Carbohydrates; Erythrocytes; Fructose; Male; Motor Neurons; Neural Conduction; Rats; Retina; Rhodanine; Sciatic Nerve; Sorbitol; Sugar Alcohol Dehydrogenases; Thiazoles; Thiazolidines | 1985 |